BioAtla (NASDAQ:BCAB) Price Target Lowered to $5.00 at JMP Securities

BioAtla (NASDAQ:BCAB) had its target price decreased by equities research analysts at JMP Securities from $12.00 to $5.00 in a research note issued on Thursday, Benzinga reports. The firm presently has a “market outperform” rating on the stock. JMP Securities’ target price would indicate a potential upside of 125.23% from the company’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of BioAtla in a report on Wednesday, May 15th.

BioAtla Stock Performance

BCAB traded down $0.06 during trading on Thursday, hitting $2.22. The stock had a trading volume of 136,040 shares, compared to its average volume of 579,127. The company has a market capitalization of $106.78 million, a PE ratio of -0.90 and a beta of 1.23. BioAtla has a twelve month low of $1.24 and a twelve month high of $4.02. The stock has a 50 day simple moving average of $2.86 and a two-hundred day simple moving average of $2.41.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings data on Tuesday, March 26th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.12. On average, equities research analysts anticipate that BioAtla will post -1.72 EPS for the current year.

Institutional Trading of BioAtla

Several institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in shares of BioAtla in the first quarter valued at about $103,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of BioAtla in the first quarter valued at about $45,000. Acadian Asset Management LLC grew its position in shares of BioAtla by 57.6% in the first quarter. Acadian Asset Management LLC now owns 155,188 shares of the company’s stock valued at $532,000 after purchasing an additional 56,748 shares during the period. Vanguard Group Inc. grew its position in shares of BioAtla by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,099,037 shares of the company’s stock valued at $7,221,000 after purchasing an additional 17,667 shares during the period. Finally, Chase Investment Counsel Corp acquired a new position in BioAtla during the first quarter worth about $263,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.